126 research outputs found
Standing genetic variation and the evolution of drug resistance in HIV
Drug resistance remains a major problem for the treatment of HIV. Resistance
can occur due to mutations that were present before treatment starts or due to
mutations that occur during treatment. The relative importance of these two
sources is unknown. We study three different situations in which HIV drug
resistance may evolve: starting triple-drug therapy, treatment with a single
dose of nevirapine and interruption of treatment. For each of these three cases
good data are available from literature, which allows us to estimate the
probability that resistance evolves from standing genetic variation. Depending
on the treatment we find probabilities of the evolution of drug resistance due
to standing genetic variation between 0 and 39%. For patients who start
triple-drug combination therapy, we find that drug resistance evolves from
standing genetic variation in approximately 6% of the patients. We use a
population-dynamic and population-genetic model to understand the observations
and to estimate important evolutionary parameters. We find that both, the
effective population size of the virus before treatment, and the fitness of the
resistant mutant during treatment, are key-parameters that determine the
probability that resistance evolves from standing genetic variation.
Importantly, clinical data indicate that both of these parameters can be
manipulated by the kind of treatment that is used.Comment: 33 pages 6 figure
Immunovirological response to combined antiretroviral therapy and drug resistance patterns in children: 1- and 2-year outcomes in rural Uganda
Children living with HIV continue to be in urgent need of combined antiretroviral therapy (ART). Strategies to scale up and improve pediatric HIV care in resource-poor regions, especially in sub-Saharan Africa, require further research from these settings. We describe treatment outcomes in children treated in rural Uganda after 1 and 2 years of ART start
Functional and Transcriptional Induction of Aquaporin-1 Gene by Hypoxia; Analysis of Promoter and Role of Hif-1α
Aquaporin-1 (AQP1) is a water channel that is highly expressed in tissues with rapid O2 transport. It has been reported that this protein contributes to gas permeation (CO2, NO and O2) through the plasma membrane. We show that hypoxia increases Aqp1 mRNA and protein levels in tissues, namely mouse brain and lung, and in cultured cells, the 9L glioma cell line. Stopped-flow light-scattering experiments confirmed an increase in the water permeability of 9L cells exposed to hypoxia, supporting the view that hypoxic Aqp1 up-regulation has a functional role. To investigate the molecular mechanisms underlying this regulatory process, transcriptional regulation was studied by transient transfections of mouse endothelial cells with a 1297 bp 5′ proximal Aqp1 promoter-luciferase construct. Incubation in hypoxia produced a dose- and time-dependent induction of luciferase activity that was also obtained after treatments with hypoxia mimetics (DMOG and CoCl2) and by overexpressing stabilized mutated forms of HIF-1α. Single mutations or full deletions of the three putative HIF binding domains present in the Aqp1 promoter partially reduced its responsiveness to hypoxia, and transfection with Hif-1α siRNA decreased the in vitro hypoxia induction of Aqp1 mRNA and protein levels. Our results indicate that HIF-1α participates in the hypoxic induction of AQP1. However, we also demonstrate that the activation of Aqp1 promoter by hypoxia is complex and multifactorial and suggest that besides HIF-1α other transcription factors might contribute to this regulatory process. These data provide a conceptual framework to support future research on the involvement of AQP1 in a range of pathophysiological conditions, including edema, tumor growth, and respiratory diseases
Correction to: Clinical recommendations for cardiovascular magnetic resonance mapping of T1, T2, T2* and extracellular volume: A consensus statement by the Society for Cardiovascular Magnetic Resonance (SCMR) endorsed by the European Association for Cardiovascular Imaging (EACVI).
CORRECTION TO: J CARDIOVASC MAGN RESON (2017) 19: 75. DOI: 10.1186/S12968-017-0389-8: In the original publication of this article [1] the "Competing interests" section was incorrect. The original publication stated the following competing interests
The effect of a metallic particle near a spacer on flashover phenomena in SF6.
This paper presents a study of the flashover mechanism initiated by metallic particles in SF6 gas. Using a high-speed Imacon photographic camera it was established that a metallic particle near the insulator surface plays an important role in flashover development. The influence of the particle on flashover development depends on the pressure of the SF6 gas. At atmospheric pressure, the flashover was always initiated at a point on the particle farthest from the nearest electrode. At high pressures, it was found that breakdown develops from the electrode of relative positive polarity in the form of a leader. The velocity of the discharge crossing the gap increases exponentially when the distance between the particle and the insulator surface decreases
- …